LUCINAE Registry: Thoracic Cancers During Pregnancy

NCT07699861 | Recruiting

• 1 other identifier: LUCINAE Registry
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 4

Brief Summary

The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives. Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers. The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.

Conditions

Lung Cancer; Thoracic Cancer; Cancer During Pregnancy

Keywords

thoracic cancers during pregnancy; Lung cancer during pregnancy

Outcome Measures

Primary Outcomes (5)

• Timing of diagnosis

  Timing of cancer diagnosis with respect to the onset of pregnancy.

  At the moment of patient enrolment

• Modality of diagnosis

  Method used for cancer diagnosis.

  At the moment of patient enrolment

• Duration of treatment

  Duration of the treatment received during the pregnancy

  Throughout study participation, up to 5 years after delivery.

• Maternal outcome

  Survival of the mother at the end of gestation.

  At the conclusion of pregnancy.

• Fetal outcome

  Survival of the fetus at the end of gestation.

  At the conclusion of pregnancy.

Secondary Outcomes (8)

• Parental overall survival

  From thoracic cancer diagnosis until 5 years after delivery.

• Offspring's overall survival

  From birth until 5 years after birth.

• Pregnancy complications

  From pregnancy diagnosis to 1 month after delivery.

• Gestational age at delivery

  At the conclusion of pregnancy.

• Congenital abnormalities

  From birth to 30 days after birth.

Study Arms (2)

Cohort A

Retrospective patients: patients who are included in the registry only after death.

Cohort B

Prospective patients: patients who are currently treated at the participating site or will be diagnosed during the enrollment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will include all pregnant biological female patients, of any ethnicity, with a diagnosis of thoracic cancer at any stage and men with a diagnosis of thoracic cancer who were undergoing active oncological treatment at the time their partner conceived their child.

You may qualify if:

• \. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:
• Patients receiving a diagnosis of thoracic cancer during pregnancy
• Patients who became pregnant while having active thoracic cancer
• Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.
• \. Available information about pregnancy outcomes
• \. Age ≥ 18 years

You may not qualify if:

• \. Patient missing data about thoracic cancer stage and diagnosis
• \. For retrospective patients, documented refusal to the use of clinical data for research purposes

Sponsors & Collaborators

• Oncology Institute of Southern Switzerland: lead
• Clinical Trial Unit Ente Ospedaliero Cantonale: collaborator

Study Sites (4)

Kantonsspital Baden

Baden, Switzerland

RECRUITING

Istituto Oncologico della Svizzera Italiana (IOSI)

Bellinzona, Switzerland

RECRUITING

Geneva University Hospital (HUG)

Geneva, Switzerland

RECRUITING

Kantonsspital Winterthur

Winterthur, Switzerland

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Martina Imbimbo

CONTACT

+41918119631; Martina.Imbimbo@eoc.ch

Luigi Tortola

CONTACT

+41 91 811 96 68; luigi.tortola@eoc.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 11, 2026
• First Posted: July 13, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 1, 2035
• Study Completion (Estimated): December 1, 2035
• Last Updated: July 13, 2026

Record last verified: 2026-07

Locations

CH (4)